SCHEMBL30748853

SCHEMBL30748853

CC1(C)CN(c2ccc(Oc3ccccc3)cc2)c2nc(CO)ncc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LTA4H P09960 2/20 0.35
GAA P10253 1/20 0.34
MAPK1 P28482 2/20 0.34
TNK2 Q07912 1/20 0.34
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
PLCG1 P19174 1/20 0.33
SORD Q00796 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
XIAP P98170 1/20 0.33
BIRC2 Q13490 1/20 0.33
MCHR2 Q969V1 1/20 0.32
MCHR1 Q99705 1/20 0.32
LCK P06239 1/20 0.32
KDR P35968 1/20 0.32
TEK Q02763 1/20 0.32
HRH4 Q9H3N8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749020 0.84 PIN1 (0.40) LTA4HTNK2PLCG1SMN1; SMN2HRH4
SCHEMBL30749122 0.82 TNK2 (0.36) POLBL3MBTL1LTA4HTNK2PLCG1
SCHEMBL30748969 0.81 PLCG1 (0.35) TNK2PLCG1SMN1; SMN2MCHR2MCHR1
SCHEMBL30749008 0.81 PLCG1 (0.33) LTA4HTNK2PLCG1SMN1; SMN2MCHR2
SCHEMBL31691357 0.81 MCHR2 (0.33) LTA4HMCHR2MCHR1HRH4
SCHEMBL30749104 0.79 PDE4B (0.43) RXRARXRBRXRGSORD
SCHEMBL30748758 0.78 APP (0.37) LTA4H
SCHEMBL30749006 0.75 EGLN1 (0.44) POLBL3MBTL1LTA4HPLCG1
SCHEMBL30749080 0.74 PSEN1 (0.39) POLBL3MBTL1LTA4HSORDMCHR2
SCHEMBL30748811 0.73 ADRA1D (0.35) RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT POLB 683/4885L3MBTL1 517/4885LTA4H 669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.